These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11985384)

  • 21. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
    Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
    Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial.
    Scott TF; You X; Foulds P
    Neurol Res; 2011 Jun; 33(5):549-52. PubMed ID: 21669126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.
    Rudick RA; Cutter GR; Baier M; Weinstock-Guttman B; Mass MK; Fisher E; Miller DM; Sandrock AW
    Mult Scler; 2005 Dec; 11(6):626-34. PubMed ID: 16323317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study.
    Fernández O; Arbizu T; Izquierdo G; Martínez-Yélamos A; Gata JM; Luque G; de Ramón E
    Acta Neurol Scand; 2003 Jan; 107(1):7-11. PubMed ID: 12542507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.
    Milanese C; La Mantia L; Palumbo R; Martinelli V; Murialdo A; Zaffaroni M; Caputo D; Capra R; Bergamaschi R;
    J Neurol Neurosurg Psychiatry; 2003 Dec; 74(12):1689-92. PubMed ID: 14638892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis.
    Granger CV; Wende K; Brownscheidle CM
    Am J Phys Med Rehabil; 2003 Jun; 82(6):427-36. PubMed ID: 12820784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.
    Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A
    Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
    Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
    Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Saccà F; Russo CV; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2018 Jan; 19():50-54. PubMed ID: 29128737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis.
    Coppola G; Lanzillo R; Florio C; Orefice G; Vivo P; Ascione S; Schiavone V; Pagano A; Vacca G; De Michele G; Morra VB
    Eur J Neurol; 2006 Sep; 13(9):1014-21. PubMed ID: 16930370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.
    Arbizu T; Alvarez-Cermeño JC; Decap G; Fernández O; Uría DF; García Merino A; Izquierdo G; Montalbán X
    Acta Neurol Scand; 2000 Oct; 102(4):209-17. PubMed ID: 11071104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
    Vollmer TL; Sorensen PS; Selmaj K; Zipp F; Havrdova E; Cohen JA; Sasson N; Gilgun-Sherki Y; Arnold DL;
    J Neurol; 2014 Apr; 261(4):773-83. PubMed ID: 24535134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
    Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.